The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Executive summary of the KDIGO 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease
Open accessAbstract
The Kidney Disease: Improving Global Outcomes (KDIGO) 2021 Clinical Practice Guideline for the Management of Blood Pressure in Chronic Kidney Disease for patients not receiving dialysis represents an update to the KDIGO 2012 guideline on this topic. Development of this guideline update followed a rigorous process of evidence review and appraisal. Guideline recommendations are based on systematic reviews of relevant studies and appraisal of the quality of the evidence. The strength of recommendations is based on the "Grading of Recommendations Assessment, Development and Evaluation" (GRADE) approach. The scope includes topics covered in the original guideline, such as optimal blood pressure targets, lifestyle interventions, antihypertensive medications, and specific management in kidney transplant recipients and children. Some aspects of general and cardiovascular health, such as lipid and smoking management, are excluded. This guideline also introduces a chapter dedicated to proper blood pressure measurement since all large randomized trials targeting blood pressure with pivotal outcomes used standardized preparation and measurement protocols adhered to by patients and clinicians. Based on previous and new evidence, in particular the Systolic Blood Pressure Intervention Trial (SPRINT) results, we propose a systolic blood pressure target of less than 120 mm Hg using standardized office reading for most people with chronic kidney disease (CKD) not receiving dialysis, the exception being children and kidney transplant recipients. The goal of this guideline is to provide clinicians and patients a useful resource with actionable recommendations supplemented with practice points. The burden of the recommendations on patients and resources, public policy implications, and limitations of the evidence are taken into consideration. Lastly, knowledge gaps and recommendations for future research are provided.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Brenner, B. M., Cooper, M. E., de Zeeuw, D., Keane, W. F., Mitch, W. E., Parving, H.-H., Remuzzi, G., Snapinn, S. M., Zhang, Z., & Shahinfar, S. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011161 · Cited by 7,493
Whelton, P. K., Carey, R. M., Aronow, W. S., Casey, D. E., Collins, K. J., Dennison Himmelfarb, C., DePalma, S. M., Gidding, S., Jamerson, K. A., Jones, D. W., et al. (2018) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2017.11.006 · Cited by 6,616
Self-citationA Randomized Trial of Intensive versus Standard Blood-Pressure Control
The SPRINT Research Group (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1511939 · Cited by 6,325
Lewis, E. J., Hunsicker, L. G., Clarke, W. R., Berl, T., Pohl, M. A., Lewis, J. B., Ritz, E., Atkins, R. C., Rohde, R., & Raz, I. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa011303 · Cited by 5,987
Ettehad, D., Emdin, C. A., Kiran, A., Anderson, S. G., Callender, T., Emberson, J., Chalmers, J., Rodgers, A., & Rahimi, K. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01225-8 · Cited by 3,755 · cited 9×
“There is limited evidence on the use of specific antihypertensive agents to treat high BP in CKD.”
ResultInfluentialEffects of intensive blood-pressure control in type 2 diabetes mellitus
(2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001286 · Cited by 3,598
Effect of finerenone on chronic kidney disease outcomes in type 2 diabetes
Bakris, G. L., Agarwal, R., Anker, S. D., Pitt, B., Ruilope, L. M., Rossing, P., Kolkhof, P., Nowack, C., Schloemer, P., Joseph, A., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2025845 · Cited by 2,935 · cited 1×
“In the Finerenone in Reducing Kidney Failure and Disease Progression in Diabetic Kidney Disease (FIDELIO-DKD) study, finerenone showed kidney and cardiovascular protection with modest effects on SBP (2–3 mm Hg lower) but a higher incidence of hyperkalemia.(27) At the writing of this guideline, finerenone has not been…”
BackgroundWilliams, B., Mancia, G., Spiering, W., Agabiti Rosei, E., Azizi, M., Burnier, M., Clement, D. L., Coca, A., de Simone, G., Dominiczak, A., et al. (2018) · Journal of Hypertension · doi:10.1097/hjh.0000000000001940 · Cited by 2,885
Klahr, S., Levey, A. S., Beck, G. J., Caggiula, A. W., Hunsicker, L., Kusek, J. W., & Striker, G. (1994) · New England Journal of Medicine · doi:10.1056/nejm199403313301301 · Cited by 2,328
Maschio, G., Alberti, D., Janin, G., Locatelli, F., Mann, J. F. E., Motolese, M., Ponticelli, C., Ritz, E., & Zucchelli, P. (1996) · New England Journal of Medicine · doi:10.1056/nejm199604113341502 · Cited by 1,766
Self-citationWilliamson (2019) · doi:10.1001/jama.2018.21442 · Cited by 1,246
Strict Blood-Pressure Control and Progression of Renal Failure in Children
(2009) · New England Journal of Medicine · doi:10.1056/nejmoa0902066 · Cited by 956
Ruggenenti, P., Perna, A., Gherardi, G., Garini, G., Zoccali, C., Salvadori, M., Scolari, F., Schena, F. P., & Remuzzi, G. (1999) · The Lancet · doi:10.1016/s0140-6736(98)10363-x · Cited by 910
The modification of diet in renal disease study group
Beck, G. J., Berg, R. L., Coggins, C. H., Gassman, J. J., Hunsicker, L. G., Schluchter, M. D., & Williams, G. W. (1991) · Controlled Clinical Trials · doi:10.1016/0197-2456(91)90069-x · Cited by 818
Efficacy and Safety of Benazepril for Advanced Chronic Renal Insufficiency
Hou, F. F., Zhang, X., Zhang, G. H., Xie, D., Chen, P. Y., Zhang, W. R., Jiang, J. P., Liang, M., Wang, G. B., Liu, Z. R., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053107 · Cited by 710
Self-citationRuggenenti, P., Perna, A., Loriga, G., Ganeva, M., Ene-Iordache, B., Turturro, M., Lesti, M., Perticucci, E., Chakarski, I. N., Leonardis, D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)71082-5 · Cited by 644
Nerenberg, K. A., Zarnke, K. B., Leung, A. A., Dasgupta, K., Butalia, S., McBrien, K., Harris, K. C., Nakhla, M., Cloutier, L., Gelfer, M., et al. (2018) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2018.02.022 · Cited by 573
Self-citationXie, X., Liu, Y., Perkovic, V., Li, X., Ninomiya, T., Hou, W., Zhao, N., Liu, L., Lv, J., Zhang, H., et al. (2016) · American Journal of Kidney Diseases · doi:10.1053/j.ajkd.2015.10.011 · Cited by 479
Effects of Intensive BP Control in CKD
Cheung, A. K., Rahman, M., Reboussin, D. M., Craven, T. E., Greene, T., Kimmel, P. L., Cushman, W. C., Hawfield, A. T., Johnson, K. C., Lewis, C. E., et al. (2017) · Journal of the American Society of Nephrology · doi:10.1681/asn.2017020148 · Cited by 475
Self-citationBlood Pressure Lowering Treatment Trialists' Collaboration (2013) · BMJ · doi:10.1136/bmj.f5680 · Cited by 263
Tong, A., Gill, J., Budde, K., Marson, L., Reese, P. P., Rosenbloom, D., Rostaing, L. P. E., Wong, G., Josephson, M. A., Pruett, T. L., et al. (2017) · Transplantation · doi:10.1097/tp.0000000000001774 · Cited by 144
Self-citationBeddhu, S., Chertow, G. M., Greene, T., Whelton, P. K., Ambrosius, W. T., Cheung, A. K., Cutler, J. A., Fine, L. J., Boucher, R. E., Wei, G., et al. (2018) · Journal of the American Heart Association · doi:10.1161/jaha.118.009326 · Cited by 121
Self-citationBeddhu, S., Rocco, M. V., Toto, R. D., Craven, T. E., Greene, T., Bhatt, U. Y., Cheung, A. K., Cohen, D. L., Freedman, B. I., Hawfield, A. T., et al. (2017) · Annals of Internal Medicine · doi:10.7326/m16-2966 · Cited by 120
Self-citationBress, A. P., King, J. B., Kreider, K. E., Beddhu, S., Simmons, D. L., Cheung, A. K., Zhang, Y., Doumas, M. N., Nord, J. W., Sweeney, M. E., et al. (2017) · Diabetes Care · doi:10.2337/dc17-0885 · Cited by 84
Self-citationPeralta, C. A., McClure, L. A., Scherzer, R., Odden, M. C., White, C. L., Shlipak, M. G., Benavente, O., & Pérgola, P. E. (2016) · Circulation · doi:10.1161/circulationaha.115.019657 · Cited by 81
Hiremath, S. S., Sapir‐Pichhadze, R., Nakhla, M. M., Gabor, J. Y., Khan, N. A., Kuyper, L. M., Ruzicka, M., Tobe, S. W., Tran, K. C., Rabi, D. M., et al. (2020) · Canadian Journal of Cardiology · doi:10.1016/j.cjca.2020.02.083 · Cited by 58
Self-citation
Cited by
Epidemiology and risk of cardiovascular disease in populations with chronic kidney disease
Matsushita, K., Ballew, S. H., Wang, A. Y.-M., Kalyesubula, R., Schaeffner, E., & Agarwal, R. (2022) · Nature Reviews Nephrology · doi:10.1038/s41581-022-00616-6 · Cited by 670
Blonde, L., Umpierrez, G. E., Reddy, S. S., McGill, J. B., Berga, S. L., Bush, M., Chandrasekaran, S., DeFronzo, R. A., Einhorn, D., Galindo, R. J., et al. (2022) · Endocrine Practice · doi:10.1016/j.eprac.2022.08.002 · Cited by 507
Al-Makki, A., DiPette, D., Whelton, P. K., Murad, M. H., Mustafa, R. A., Acharya, S., Beheiry, H. M., Champagne, B., Connell, K., Cooney, M. T., et al. (2022) · Hypertension · doi:10.1161/hypertensionaha.121.18192 · Cited by 374
Metadata
- Authors
- Cheung, A. K., Chang, T. I., Cushman, W. C., Furth, S. L., Hou, F. F., Ix, J. H., Knoll, G. A., Muntner, P., Pecoits-Filho, R., Sarnak, M. J., Tobe, S. W., Tomson, C. R. V., Lytvyn, L., Craig, J. C., Tunnicliffe, D. J., Howell, M., Tonelli, M., Cheung, M., Earley, A., & Mann, J. F. E.
- Venue
- Kidney International
- Publisher
- Elsevier BV
- Published
- 2021-03
- Volume
- 99
- Issue
- 3
- Pages
- 559-569
- ISSN
- 0085-2538 (ISSN-L)
- OpenAlex
- W3132757566
- Cited by
- 338
- References
- 28
- FWCI
- 36.81
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.